Another study demonstrates IGF2BP3 stabilizes COX6B2 mRNA via m6A modification at its 3′UTR, inducing resistance to EGFR-TKI in NSCLC by enhancing OXPHOS and nicotinamide metabolism (Lin et al., 2023). Here, IGF2BP3 is linked to non-small cell lung carcinoma.